EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Rigel Pharmaceuticals EBITDA Margin % Related Terms
Rigel Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Rigel Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RI2 vs CBIO, TRAX, GYRE: EBITDA Margin % Comparison
For the Biotechnology subindustry, Rigel Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rigel Pharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals (FRA:RI2) has a EBITDA Margin % of 23.27% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rigel Pharmaceuticals and its competitors. According to the industry distribution chart, Rigel Pharmaceuticals ranks #66 out of 945 companies in the Biotechnology industry, placing it in the top 7%.
Is Rigel Pharmaceuticals' EBITDA Margin % too high?
Rigel Pharmaceuticals' current EBITDA Margin % is 23.27%. Based on the distribution chart, Rigel Pharmaceuticals ranks #66 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rigel Pharmaceuticals has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' EBITDA Margin % compare to CBIO and TRAX?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #66 out of 945 companies for EBITDA Margin %. This places Rigel Pharmaceuticals in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rigel Pharmaceuticals and its competitors. Rigel Pharmaceuticals's current EBITDA Margin % is 23.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current EBITDA Margin % of 23.27%. The stock's GF Value™ is €23.45, compared to a current price of €29.47 — trading 25.7% above its estimated fair value. The current EBITDA Margin % is 23.27%. Rigel Pharmaceuticals' overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current EBITDA Margin % is 23.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?
Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued.
The current stock price of €29.47 is trading 25.7% above its estimated GF Value™ of €23.45.
Key valuation signals for FRA:RI2:
EBITDA Margin %: 23.27%
GF Value™: €23.45 vs. price of €29.47 (25.7% above fair value)
No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
78GF Score
Get the complete analysis for FRA:RI2
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RI2 has been successfully added to your 
